Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Morgensztern

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Cancer|March 12, 2024
The changing landscape of small cell lung cancerGiordano Fabricio Cittolin-Santos, Brendan Knapp, Bharath Ganesh, et al.
Leukemia & Lymphoma|December 29, 2004
Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literatureDaniel Morgensztern, Manuel Rosado, Orlando Silva, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 18, 2011
Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancerRamaswamy Govindan, Daniel Morgensztern, Michael D Kommor, et al.
Head & Neck|September 28, 2010
Squamous cell cancer of the head and neck with distant metastasis at presentationDavid I Kuperman, Vorachart Auethavekiat, Douglas R Adkins, et al.
Cancer|April 2, 2019
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapyDaniel Morgensztern, Amy Ko, Mary O'Brien, et al.
The Journal of Surgical Research|April 16, 2013
Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results databaseAmy C Moreno, Daniel Morgensztern, James B Yu, et al.
Future Oncology (London, England)|July 11, 2022
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomasMartin Wermke, Enriqueta Felip, Valentina Gambardella, et al.
JCO Oncology Practice|July 28, 2025
Erratum: Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung CancerRotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, et al.
JCO Oncology Practice|June 30, 2025
Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung CancerRotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, et al.
Acta Oncologica (Stockholm, Sweden)|May 5, 2016
Delayed nausea and vomiting from carboplatin doublet chemotherapySaiama N Waqar, Janelle Mann, Maria Q Baggstrom, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Cancer|March 12, 2024
The changing landscape of small cell lung cancerGiordano Fabricio Cittolin-Santos, Brendan Knapp, Bharath Ganesh, et al.
Leukemia & Lymphoma|December 29, 2004
Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literatureDaniel Morgensztern, Manuel Rosado, Orlando Silva, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 18, 2011
Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancerRamaswamy Govindan, Daniel Morgensztern, Michael D Kommor, et al.
Head & Neck|September 28, 2010
Squamous cell cancer of the head and neck with distant metastasis at presentationDavid I Kuperman, Vorachart Auethavekiat, Douglas R Adkins, et al.
Cancer|April 2, 2019
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapyDaniel Morgensztern, Amy Ko, Mary O'Brien, et al.
The Journal of Surgical Research|April 16, 2013
Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results databaseAmy C Moreno, Daniel Morgensztern, James B Yu, et al.
Future Oncology (London, England)|July 11, 2022
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomasMartin Wermke, Enriqueta Felip, Valentina Gambardella, et al.
JCO Oncology Practice|July 28, 2025
Erratum: Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung CancerRotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, et al.
JCO Oncology Practice|June 30, 2025
Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung CancerRotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, et al.
Acta Oncologica (Stockholm, Sweden)|May 5, 2016
Delayed nausea and vomiting from carboplatin doublet chemotherapySaiama N Waqar, Janelle Mann, Maria Q Baggstrom, et al.
Pageof 19